PHK
RCUS icon

Point72 Hong Kong’s Arcus Biosciences RCUS Stock Holding History

Point72 Hong Kong’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,991
Closed -$65K – 613
2025
Q2 		$65K Buy
+7,991
New +$68.3K ﹤0.01% 360
2024
Q4 		– Sell
-3,100
Closed -$47.4K – 584
2024
Q3 		$47.4K Buy
+3,100
New +$48.9K ﹤0.01% 377
2022
Q2 		– Sell
-7,774
Closed -$245K – 2323
2022
Q1 		$245K Buy
7,774
+7,325
+1,631% +$245K 0.01% 897
2021
Q4 		$18K Buy
+449
New +$17.4K ﹤0.01% 1559
2021
Q2 		– Sell
-1,202
Closed -$34K – 2280
2021
Q1 		$34K Buy
+1,202
New +$41.8K ﹤0.01% 1367
2020
Q3 		– Sell
-12,406
Closed -$307K – 1471
2020
Q2 		$307K Buy
+12,406
New +$335K 0.03% 430
2018
Q2 		– Sell
-7,656
Closed -$118K – 1137
2018
Q1 		$118K Buy
+7,656
New +$128K 0.06% 276

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Hong Kong's RCUS Position: Q3 2025 in Review

Point72 Hong Kong sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 7,991 shares — an estimated $65K sold.

Point72 Hong Kong first reported a position in RCUS in Q1 2018 and held it in 7 quarters. The position peaked at $307K in Q2 2020. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Point72 Hong Kong reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 7,991 Arcus Biosciences shares in Q3 2025, an estimated $65K.
  • Point72 Hong Kong first reported a position in Arcus Biosciences in Q1 2018 and held it in 7 quarters.
  • Point72 Hong Kong's Arcus Biosciences position peaked at $307K in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.